Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Drug Discov Today ; 25(8): 1528-1534, 2020 08.
Article in English | MEDLINE | ID: covidwho-601661

ABSTRACT

Here, we highlight recent findings on the urokinase plasminogen activator (uPA)/uPA receptor (uPAR) system that suggest its potential role as a main orchestrator of fatal progression to pulmonary, kidney, and heart failure in patients with coronavirus. Patients with prolonged background inflammation can present aberrant inflammatory reactions, well recognized as the main factors that can result in death and probably sustained by a dysregulated uPA/uPAR system. SuPAR, the soluble form of uPAR, represents a biomarker of disease progression, and its levels correlate well with comorbidities associated with the death of patients with coronavirus. New drugs that regulate the uPA/uPAR system could help treat the severe complications of highly pathogenic human coronaviruses (hCoVs), including pandemic coronavirus 2019 (COVID-19).


Subject(s)
Coronavirus Infections/physiopathology , Pneumonia, Viral/physiopathology , Receptors, Urokinase Plasminogen Activator/metabolism , Urokinase-Type Plasminogen Activator/metabolism , Animals , Biomarkers/metabolism , COVID-19 , Coronavirus Infections/drug therapy , Coronavirus Infections/virology , Disease Progression , Drug Development , Humans , Inflammation/physiopathology , Inflammation/virology , Pandemics , Pneumonia, Viral/drug therapy , Pneumonia, Viral/virology , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL